Par Pharmaceutical filed for declaratory judgment against UCB, Inc. over two patents related to an extended release tablet of levetiracetam. 3/23, Eastern District of Pennsylvania, 2:2011cv02010
Access to the full article is currently available to RPX members only. Please contact us if you need further information.
